

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Equality and health inequality impact assessment

**Finerenone for treating heart failure with preserved or mildly reduced
ejection fraction [ID6514]**

Final draft guidance (when issued)

- 1 Have any additional potential equality or health inequality issues been raised during consultation on the draft guidance? If so, how has the committee addressed these?**

This topic did not have draft guidance or an associated consultation.

- 2 Have any additional potential equality or health inequality issues been identified by the committee? If so, how has the committee addressed these?**

Several issues were raised during this appraisal including:

- A. Unequal access to specialist heart failure services. Varying by heart failure subtype and where a person lives
- B. People in more deprived areas may have higher risk of heart failure readmissions and less access to specialist care.
- C. The condition might disproportionately affect some groups including people with multiple comorbidities or frailty.
- D. Spironolactone may be less suitable for some people because of contraindication or tolerability concerns.

- 3 If the recommendations have changed after consultation, do the updated recommendations make it more difficult for a specific**

group to access the technology than other groups? If so, what are the barriers to, or difficulties with, access for this group?

The recommendations do not make it more specific for a specific group to access the technology compared to other groups.

- 4 If the recommendations have changed after consultation, has the committee made any other reasonable adjustments in the recommendations for the equality issues identified? That is, have any adjustments to the recommendations been made to remove or alleviate barriers to, or difficulties with, access to the technology needed to fulfil NICE's obligations to promote equality.**

N/A

- 5 Has the committee taken into consideration the health inequality issues in its decision-making? If so, how was this done?**

The committee concluded that issues of access to services and social deprivation may have been appropriate health inequality issues but noted they were not presented with any analysis that showed the extent of these issues. It was therefore unclear whether finerenone would reduce health inequalities and whether this should have been taken into account in its decision making.

- 6 Have the committee's considerations of equality and health inequality issues been described in the final draft guidance? If so, where?**

Yes. Section 3.13.

Approved by senior responsible officer: Adam Brooke

Date: 08/07/2026